Effectiveness and safety of early treatment with spironolactone for new-onset acute heart failure.
Cheng-Wei HuangJoon S ParkIn-Lu Amy LiuJanet S LeeSiamak KohanMathew MeffordStefanie S WuChristopher C SubjectHuong Q NguyenMing-Sum LeePublished in: Journal of hospital medicine (2024)
Early treatment with spironolactone at discharge for new-onset HFrEF in a real-world setting did not reduce the risk of HF readmission or mortality in the first year after discharge. The risk of hyperkalemia was increased.